{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-265999","form_type":"8-K","ticker":"RGNX","cik":"0001590877","company_name":"REGENXBIO Inc.","filed_at":"2021-09-07T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.711828+00:00","generated_at":"2026-06-29T05:31:05.176914+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"REGENXBIO appoints Dr. Jean Bennett and George Migausky to Board; Luke Beshar resigns","bullets":["Luke M. Beshar resigned from REGENXBIO Board effective September 3, 2021.","Dr. Jean Bennett (gene therapy pioneer, co-founder of Spark Therapeutics) elected Class II director.","George Migausky (former CFO of Dyax) elected Class III director and Audit Committee member.","Each new director received option for 20,000 shares at $34.98, plus annual retainer.","Dr. Bennett will serve on Nominating and Corp Gov Committee; Mr. Migausky on Audit Committee."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-265999","json":"https://secwatch.observer/filing/0001193125-21-265999.json","markdown":"https://secwatch.observer/filing/0001193125-21-265999.md","text":"https://secwatch.observer/filing/0001193125-21-265999.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590877/000119312521265999/0001193125-21-265999-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590877/000119312521265999/d194596d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T05:31:05.176914+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"070460d13a","claim":"Luke M. Beshar resigned as Director at REGENXBIO Inc..","evidence_excerpt":"On September 3, 2021, Luke M. Beshar notified REGENXBIO Inc. (the “Company”) of his resignation from the Board of Directors of the Company (the “Board”), effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590877/000119312521265999/0001193125-21-265999-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"3a27a4b9d4","claim":"Jean Bennett was elected as Class II director at REGENXBIO Inc..","evidence_excerpt":"On September 3, 2021, the Board, based upon the recommendation of the Nominating and Corporate Governance Committee, elected Jean Bennett, M.D., Ph.D., as a Class II director of the Company and a member of the Nominating and Corporate Governance Committee, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590877/000119312521265999/0001193125-21-265999-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Class II director"}],"fact_type":"executive_change"},{"claim_id":"46db2007ef","claim":"George V. Migausky was elected as Class III director at REGENXBIO Inc..","evidence_excerpt":"On September 3, 2021, the Board, based upon the recommendation of the Nominating and Corporate Governance Committee, elected George V. Migausky as a Class III director of the Company and a member of the Audit Committee, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590877/000119312521265999/0001193125-21-265999-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Class III director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}